BMS and Gilead rule in the CAR-T space. Off-the-shelf developers aren’t trying to change that.

Summary

BMS and Gilead are identified as dominant players in the CAR-T therapeutic space, with off-the-shelf CAR-T developers not attempting to disrupt their market position. This article appears to be a market analysis headline without specific clinical, financial, or regulatory details.